Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zinc acexamate versus placebo in compensated advanced chronic liver disease
2021-000680-74Phase 3Active
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic liver disease (CLD) comparing Zinc acexamate with Placebo (2 arms). Primary endpoints: Occurrence of time-dependent clinical events during study follow-up and Distribution of clinically significant portal hypertension risk by ANTICIPATE model. Started Jun 2021; status: active.
02
Drugs
zinc acexamate
03
Conditions
chronic liver disease (CLD)
Beyond the preview
Go deeper on 2021-000680-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000680-74.